New Clinical Data Positive For Korean Biosimilars
This article was originally published in PharmAsia News
Executive Summary
New clinical study data have been presented to a major international meeting on Samsung Bioepis and Celltrion's major biosimilar contenders as well as Boryung Pharm's hypertension therapy, all of which are South Korean drugs carrying their developer’s ambitions of overseas market launches or expansion.
You may also be interested in...
Samsung Prepping For First Biosimilar Launch
Samsung Bioepis' biosimilar version of Amgen's rheumatoid arthritis blockbuster Enbrel (etanercept) is set to become the firm’s first biosimilar product to hit the market, possibly being released in South Korea late this year and in Europe in the first half of next year.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.